Clinical Trial Update: Evaluate Bioequivalence of Voriconazole(200mg/Vial) . [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating bioequivalence of voriconazole 200 mg per vial completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antimycotic Use For Systemic Infections
• Systemic Fungal Infection

Drugs mentioned

• VORICONAZOLE (Voriconazole)

Snippet

Sponsor: Yung Shin Pharm. Ind. Co., Ltd. | Conditions: Antimycotic for Systematic Use | Phase 4 | Status: COMPLETED